Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
-To compare the efficacy responses of CP-690,550 (5 mg BID and 10 mg BID) versus placebo following 24 weeks of CP-690,550 treatment and subsequent withdrawal of active treatment at various timepoints during the 16-week double-blind active or placebo treatment period in subjects with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy. -To evaluate the regain of efficacy responses of CP-690,550 (5 mg BID and 10 mg BID) following 4-16 weeks of CP-690,550 treatment withdrawal and subsequent re-treatment in subjects with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy. -To evaluate the safety and tolerability of CP-690,550 (5 mg BID and 10 mg BID) in subjects with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy.
Critère d'inclusion
- Chronic plaque psoriasis